Bio-Techne Corp

As of June 30, 2026, Bio-Techne Corporation Unsponsored Brazilian Depository Receipt Repr 0.033333333 Sh carries a market capitalization of 57.22B, placing it among publicly traded companies globally. Its enterprise value stands at 57.35B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Bio-Techne Corporation Unsponsored Brazilian Depository Receipt Repr 0.033333333 Sh's next confirmed earnings release is scheduled for November 3, 2026.

As of June 30, 2026, Bio-Techne Corporation Unsponsored Brazilian Depository Receipt Repr 0.033333333 Sh has 4.70B shares outstanding.

As of June 30, 2026, Bio-Techne Corporation Unsponsored Brazilian Depository Receipt Repr 0.033333333 Sh trades at a trailing price-to-earnings ratio of 60.81. The price-to-sales ratio is 9.10, and the price-to-book ratio stands at 5.25.

As of June 30, 2026, Bio-Techne Corporation Unsponsored Brazilian Depository Receipt Repr 0.033333333 Sh trades at an EV/EBITDA multiple of 31.77 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 9.13 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 44.05 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Bio-Techne Corporation Unsponsored Brazilian Depository Receipt Repr 0.033333333 Sh trades at an EV/FCF ratio of 41.02, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 57.35B versus a market cap of 57.22B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Bio-Techne Corporation Unsponsored Brazilian Depository Receipt Repr 0.033333333 Sh maintains a current ratio of 4.55, meaning it holds 4.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 13.71, indicating elevated leverage, while an interest coverage ratio of 36.27 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Bio-Techne Corporation Unsponsored Brazilian Depository Receipt Repr 0.033333333 Sh posted a return on equity (ROE) of 9.03, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 7.99 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 7.07, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 7.95, useful for judging operating efficiency across full business cycles. The company generates approximately 2.04M in revenue per employee across its workforce of 3,075.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.16 indicates how many times Bio-Techne Corporation Unsponsored Brazilian Depository Receipt Repr 0.033333333 Sh sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Bio-Techne Corporation Unsponsored Brazilian Depository Receipt Repr 0.033333333 Sh recorded 304.03M in income tax expense. That works out to an effective tax rate of 24.44, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.24B, leaving 940.04M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 21, 2026, Bio-Techne Corporation Unsponsored Brazilian Depository Receipt Repr 0.033333333 Sh's stock has gained approximately 6.09% over the past 52 weeks. The 50-day moving average sits at 11.62, while the 200-day moving average is 11.24.

Over the twelve months ended June 30, 2026, Bio-Techne Corporation Unsponsored Brazilian Depository Receipt Repr 0.033333333 Sh generated 6.28B in revenue and converted that into 940.04M in net income, yielding earnings per share of 0.20. EBITDA reached 1.81B, while operating income came in at 1.41B.

As of June 30, 2026, Bio-Techne Corporation Unsponsored Brazilian Depository Receipt Repr 0.033333333 Sh holds 1.37B in cash and equivalents against 1.49B in total debt, resulting in a net debt position of -334.50M. Total book value stands at 10.90B, with working capital of 3.00B providing operational flexibility.

Bio-Techne Corporation Unsponsored Brazilian Depository Receipt Repr 0.033333333 Sh produced 1.51B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -149.13M in capital expenditures, free cash flow totaled 1.36B - equivalent to 0.29 per share.

Over the twelve months ended June 30, 2026, Bio-Techne Corporation Unsponsored Brazilian Depository Receipt Repr 0.033333333 Sh posted a gross margin of 65.77, reflecting its pricing power and cost economics. The operating margin of 22.44 and net profit margin of 14.97 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Bio-Techne Corporation Unsponsored Brazilian Depository Receipt Repr 0.033333333 Sh paid dividends of 0.05 per share. The dividend payout ratio of 27.45 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 2.36, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 1.53, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Bio-Techne Corporation Unsponsored Brazilian Depository Receipt Repr 0.033333333 Sh shareholders.

Bio-Techne Corporation Unsponsored Brazilian Depository Receipt Repr 0.033333333 Sh's most recent stock split took place on November 30, 2022 with a 1:4 split ratio.

As of June 30, 2026, Bio-Techne Corporation Unsponsored Brazilian Depository Receipt Repr 0.033333333 Sh has an Altman Z-Score of 17.26, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.